Clinical preferences and treatment attitudes among urologists, gynecologists, and geriatricians: An independent online questionnaire survey for comparison of treatment choices in the management of overactive bladder [PDF]
, 2022 Objective Overactive bladder (OAB) is a common clinical problem with associated morbidities both in men and women. Although real-life management strategies have been examined among urologists (URO), treatment choices may differ between different ...
Ahmet Tahra +17 more
core +2 more sources
Risk of delirium associated with antimuscarinics in older adults: A case‐time‐control study [PDF]
, 2022 BACKGROUND: Older adults are at an increased risk of delirium because of age, polypharmacy, multiple comorbidities and acute illness. Antimuscarinics are the backbone of the pharmacological management of overactive bladder.
Te‐Yuan Chyou +4 more
core +1 more source
The urothelium and lamina propria as an alternative target for clinical antimuscarinics [PDF]
, 2022 Introduction: Overactive bladder is the most common type of bladder dysfunction and involves spontaneous contractions of the urinary bladder during the filling phase. The first-line pharmaceutical therapies for managing this disorder are antimuscarinics (
Moro, Christian; id_orcid +2 more
core +1 more source
The age-stratified overall DDDs of antimuscarinics for treatment of female LUTS.
, 2019 The age-stratified overall DDDs of antimuscarinics for treatment of female LUTS.
Ling-Ying Wu (7470542) +6 more
core +1 more source
Journal of the Formosan Medical Association, 2014 Overactive bladder symptom score (OABSS) was developed by a Japanese urologist and is widely used in Asian countries. The aim of this study was to develop and validate a Chinese OABSS for assessing overactive bladder (OAB) and treatment outcome after ...
Eric Chieh-Lung Chou +6 more
doaj +1 more source
Therapeutic Advances in Urology, 2016 Mirabegron, is the only β-3 adrenoreceptor (AR) agonist available for the treatment of overactive bladder (OAB). To assess the efficacy and tolerability of this novel drug therapy, two phase II and six phase III Astellas-sponsored trials have been ...
Ganesh Thiagamoorthy +3 more
doaj +1 more source
Acta Medica Indonesiana, 2020 Background: overactive bladder (OAB) affects 17-41% older adults in community dwelled setting. For several years, antimuscarinics have been validated as the first-line medical treatment for OAB.
Ervandy Rangganata +2 more
doaj +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah +4 more
wiley +1 more source
Overall and age-stratified prevalence for women receiving antimuscarinics for treatment of LUTS.
, 2019 Overall and age-stratified prevalence for women receiving antimuscarinics for treatment of LUTS.
Ling-Ying Wu (7470542) +6 more
core +1 more source
Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR) protocol. [PDF]
BMJ OpenIntroduction Overactive bladder (OAB) is a condition characterised by urinary urgency, often accompanied by frequency and nocturia. Antimuscarinics and β3 receptor agonists are first-line therapies that improve urinary symptoms and the quality of life ...
Yamamoto T +23 more
europepmc +2 more sources